Dual RPDD and ODD for FL118 in osteosarcoma create regulatory incentives that may accelerate development for a rare, aggressive pediatric/AYA bone cancer with limited recurrent-disease options. FL118 ...
The FDA has approved the antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd; Datroway) for adult patients with ...
Genomic assays have become indispensable tools in the management of early-stage invasive breast cancer, helping oncologists ...
Targeting KMA seeks to spare normal immunoglobulin-producing plasma cells, differentiating from BCMA-directed CAR T ...
Why frontline CLL care shifts to zanubrutinib: simple daily BTK inhibitor therapy cuts infusions, eases pill burden, adds ...
In the SEQUOIA trial, the BTK inhibitor zanubrutinib was delivered as a continuous dose in frontline chronic lymphocytic ...
Six-year Sequoia data show zanubrutinib in frontline CLL extends PFS far beyond bendamustine‑rituximab, delaying next ...
Six-year Sequoia data show zanubrutinib in frontline CLL extends PFS far beyond bendamustine‑rituximab, delaying next ...
Lipsky,MD, highlights 6-year follow-up data from the phase 3 SEQUOIA trial (NCT03336333) showing that the BTK inhibitor ...
William asks the question many patients raise explicitly or implicitly: “Do these data really apply to me?” Dr. Wu answers ...
The widest real-world gap Dr. Wu sees is surveillance adherence. Patients feel well on an oral tyrosine kinase inhibitor (TKI ...
Imetelstat achieved an approximate doubling of median overall survival versus best available therapy (HR, 0.512; P = .003) in closely matched post–JAK inhibitor myelofibrosis cohorts.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results